Details for New Drug Application (NDA): 021144
✉ Email this page to a colleague
The generic ingredient in KETEK is telithromycin. Additional details are available on the telithromycin profile page.
Summary for 021144
Tradename: | KETEK |
Applicant: | Sanofi Aventis Us |
Ingredient: | telithromycin |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 400MG | ||||
Approval Date: | Apr 1, 2004 | TE: | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 300MG | ||||
Approval Date: | Feb 9, 2005 | TE: | RLD: | No |
Expired US Patents for NDA 021144
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sanofi Aventis Us | KETEK | telithromycin | TABLET;ORAL | 021144-002 | Feb 9, 2005 | ⤷ Subscribe | ⤷ Subscribe |
Sanofi Aventis Us | KETEK | telithromycin | TABLET;ORAL | 021144-001 | Apr 1, 2004 | ⤷ Subscribe | ⤷ Subscribe |
Sanofi Aventis Us | KETEK | telithromycin | TABLET;ORAL | 021144-002 | Feb 9, 2005 | ⤷ Subscribe | ⤷ Subscribe |
Sanofi Aventis Us | KETEK | telithromycin | TABLET;ORAL | 021144-001 | Apr 1, 2004 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription